| Literature DB >> 28246466 |
Abstract
Endoscopic submucosal dissection (ESD) of superficial esophageal cancer has been increasingly used as an alternative to surgery because it is minimally invasive and has a high rate of en bloc resection. However, a high rate of esophageal stricture is observed after ESD for large lesions, which can dramatically decrease the patient's quality of life. Stricture prevention is necessary to allow for endoscopic therapy to expand. We, herein, review the most recent evidence and discuss the role of the metallic self-expandable stent and the biodegradable stent in esophageal stricture prevention. Limited studies suggested that prophylactic stenting could reduce the stricture rate without increasing the number of complications. In addition, the number of bougie dilation procedures was significantly lower with stent placement. Esophageal stenting is a promising option for post-ESD stricture prevention. However, current evidence is too preliminary to formulate practice standards. Future studies are needed to further validate the efficacy and safety of prophylactic stenting and determine the best strategy for stricture prevention. Stent migration is the most common complication. A new stent that has advantages of a low migration rate and minimal tissue reaction will need to be developed. Therefore, randomized controlled trials with long-term follow-up periods are required before prophylactic stenting could be considered a valid option to prevent post-ESD stricture.Entities:
Keywords: Biodegradable stent; Endoscopic submucosal dissection; Esophageal stricture; Metallic self-expandable stent; Stricture prevention
Mesh:
Year: 2017 PMID: 28246466 PMCID: PMC5311102 DOI: 10.3748/wjg.v23.i6.931
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Studies using esophageal stenting to prevent post-endoscopic submucosal dissection stricture
| Ye et al[ | Cohort | circumferential | Fully-covered self-expandable metallic stents (CZES stent; Sigma, China) | 12 wk | 17.4% | 17.4% |
| Wen et al[ | RCT | mucosal defect > 3/4 | Fully-covered self-expandable metallic stents (CZES stent; Sigma, China) | 8 wk | 18.2% | 18.2% |
| Saito et al[ | Case report | mucosal defect > 3/4 | PLLA esophageal stent (Tanaka-Marui stent; Marui Textile Machinery Co., Japan) | Self-degradable | 0 | 0 |
| Saito et al[ | Case report | mucosal defect > 3/4 | PLLA esophageal stent (Tanaka-Marui stent; Marui Textile Machinery Co., Japan) | Self-degradable | 0 | 77.0% |
RCT: Randomized controlled trial; PLLA: Poly-L-lactic acid.